Currently, there are 400.73M common shares owned by the public and among those 395.07M shares have been available to trade.
The company’s stock has a 5-day price change of 5.20% and -37.33% over the past three months. DXCM shares are trading -44.05% year to date (YTD), with the 12-month market performance down to -16.57% lower. It has a 12-month low price of $62.34 and touched a high of $142.00 over the same period. DXCM has an average intraday trading volume of 5.58 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.39%, -1.12%, and -36.98% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Dexcom Inc (NASDAQ: DXCM) shares accounts for 94.64% of the company’s 400.73M shares outstanding.
It has a market capitalization of $27.82B and a beta (3y monthly) value of 1.18. The stock’s trailing 12-month PE ratio is 42.78, while the earnings-per-share (ttm) stands at $1.62. The company has a PEG of 1.86 and a Quick Ratio of 2.48 with the debt-to-equity ratio at 1.07. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.89% over the week and 2.72% over the month.
Earnings per share for the fiscal year are expected to increase by 11.67%, and 18.52% over the next financial year.
Looking at the support for the DXCM, a number of firms have released research notes about the stock. Robert W. Baird stated their Neutral rating for the stock in a research note on July 26, 2024, with the firm’s price target at $161-$80. JP Morgan coverage for the Dexcom Inc (DXCM) stock in a research note released on July 26, 2024 offered a Neutral rating with a price target of $75. Redburn Atlantic was of a view on May 30, 2024 that the stock is Neutral, while RBC Capital Mkts gave the stock Outperform rating on March 12, 2024, issuing a price target of $165. Morgan Stanley on their part issued Equal-Weight rating on May 30, 2023.
